General
Preferred name
TAFLUPROST
Synonyms
AFP-168 ()
MK2452 ()
AFP-168,MK2452 ()
Saflutan ()
MK-2452 ()
Zioptan ()
Tafluprost-d4 ()
P&D ID
PD009195
CAS
209860-87-7
Tags
prodrug
natural product
drug
available
Approved by
FDA
First approval
2012
Drug Status
approved
Drug indication
Glaucoma/ocular hypertension
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Tafluprost is a prostaglandin analogue.
(GtoPdb)
METABOLISM
Tafluprost is an ester prodrug which is rapidly hydrolyzed by corneal esterases to form its biologically active acid metabolite. Tafluprost acid is further metabolized via fatty acid β-oxidation and phase II conjugation into 1,2,3,4-tetranor acid. ;
ABSORPTION
Following instillation, tafluprost is absorbed through the cornea and is hydrolyzed to the biologically active acid metabolite, tafluprost acid. Tafluprost is an ester which makes the drug lipophillic enough to be quickly absorbed through. When administered to the eye, the peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax) of tafluprost acid in healthy subjects was 26 pg/mL and 10 minutes respectively. a; AUC, tafluprost acid = 394 pg*min/mL - 432 pg*min/mL.
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
17
AdooQ Bioactive Compound Library
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
33
Molecular Weight
452.24
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
12
Ring Count
2
Aromatic Ring Count
1
cLogP
4.68
TPSA
75.99
Fraction CSP3
0.56
Chiral centers
4.0
Largest ring
6.0
QED
0.27
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Immunology/Inflammation
Target
PGF2??
PTGFR
Prostaglandin Receptor
Indication
glaucoma, ocular hypertension
MOA
Prostaglandin inhibitor
Source data
